Tirzepatide

Generic Name
Tirzepatide
Brand Names
Mounjaro
Drug Type
Biotech
Chemical Formula
-
CAS Number
2023788-19-2
Unique Ingredient Identifier
OYN3CCI6QE
Background

Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor agonists in preclinical and clinical trials.

Tirzepatide comprises a 39 amino acid linear synthetic peptide conjugated to a C20 fatty diacid moiety. Its protein sequence was based on the sequence of endogenous GIP, and its pharmacological action on GLP-1 receptors is comparable to endogenous GIP; however, the long half-life of tirzepatide allows for once-weekly dosing. Tirzepatide was approved by the FDA on May 13, 2022, for the treatment of adults with type 2 diabetes, making it the first and only GIP and GLP-1 receptor agonist for this indication. On September 15, 2022, tirzepatide was also approved by the European Commission.

Indication

Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. In Europe, it may be used as monotherapy or in combination with other drugs used to treat diabetes.

This drug has not been studied in patients with a history of pancreatitis. Tirzepatide is not indicated for use in patients with type 1 diabetes mellitus.

Associated Conditions
Type 2 Diabetes Mellitus
Associated Therapies
-
Clinical Trials
Related News
kesq.com
·

Compounded semaglutide associated with at least 10 deaths, Novo Nordisk CEO warns

Novo Nordisk CEO warns of 100 hospitalizations and 10 deaths linked to compounded semaglutide, not produced by Novo Nordisk. FDA data shows risks of compounded drugs, which are not FDA-approved and not closely regulated. Semaglutide remains on the FDA shortages list, despite Novo Nordisk's efforts to address supply issues.
ynetnews.com
·

Counterfeit diabetes, weight-loss drugs raise alarm after series of fatalities

Novo Nordisk warns counterfeit semaglutide linked to 10 deaths, 100+ hospitalizations in U.S. FDA yet to confirm, compounded versions lack oversight, raising safety concerns.
amp.scmp.com
·

Hong Kong approves celebrity weight-loss drug, but experts say it's not just to look good

Mounjaro, a new weight-loss drug by Eli Lilly, approved in Hong Kong for treating obesity and type 2 diabetes, targets two hormones. It joins other drugs like Ozempic, which have seen global shortages due to celebrity endorsements. Eli Lilly advises Mounjaro is for adults with obesity or overweight conditions and related medical issues.
express.co.uk
·

First death connected to weight loss jab as nurse dies after two doses

Susan McGowan, an NHS bed manager, died after taking two doses of the weight loss drug Mounjaro, leading to the first confirmed fatality linked to a GLP-1 agonist. Her death certificate cites multiple organ failure, septic shock, and pancreatitis, with Mounjaro usage recorded as a contributing element. The NHS yellow card scheme received 208 reports including 31 serious incidents and one suspected male death in his sixties. The NHS plans a phased rollout of Mounjaro, initially offering it to the most severely obese and unwell.
sciencemediacentre.org
·

Expert Comments on the Risks and Benefits of Tirzepatide Following the Death of Susan McGowan

Experts discuss tirzepatide's safety and benefits after a UK death linked to the drug, highlighting the need for high-quality trials and the importance of the 'yellow card scheme' for reporting side effects.
dallasnews.com
·

FDA adds new warning to weight loss drugs including Wegovy

FDA warns GLP-1 receptor agonists like Ozempic and Wegovy increase risk of pulmonary aspiration under anesthesia due to slowed stomach emptying. Patients advised to inform doctors of GLP-1 use before surgery.
clinicaltrialsarena.com
·

Viking stock fluctuates amid manufacturing concerns with obesity pill

Viking Therapeutics' stock surged on positive Phase I data for its obesity pill VK2735 but fell due to analyst concerns over manufacturing. The trial showed 6.8% weight loss in high-dose cohort. Viking plans a 13-week Phase II study in Q4 2024. The company also revealed advanced data from a subcutaneous version, indicating potential competition with Eli Lilly's Mounjaro.

Related Clinical Trials:

Phase 1 Study to Evaluate the Safety and Tolerability of VK2735
VK2735 for Weight Management Phase 2
jdsupra.com
·

Compounded GLP-1 Drugs: is the Party Over? These Are the Legal and Regulatory Issues

GLP-1 drugs, initially approved for diabetes, gained FDA approval for weight management in 2022. Despite patent monopolies, compounded copies proliferated due to drug shortages, though recent FDA actions to resolve shortages threaten this market. Companies must prepare for potential litigation and regulatory changes.
clinicaltrialsarena.com
·

Endeveco Bio spin-off to launch obesity trial

Endevica Bio launches spin-off Abisati to accelerate obesity candidate 710GO into clinical trials, aiming for Phase I in 2025. 710GO, a peptide leveraging the melanocortin system, showed safe and effective weight loss in preclinical studies, with potential to avoid side effects and 'bounce back' weight gain.
kff.org
·

Medicaid Coverage of and Spending on GLP-1s

GLP-1 drugs, effective for obesity treatment, face issues of high cost and limited Medicaid coverage. 13 states cover GLP-1s for obesity, with prior authorization and BMI requirements common. Medicaid prescriptions and spending on GLP-1s have surged, driven by Ozempic, Wegovy, and Mounjaro. States weigh cost against potential long-term savings from reduced chronic disease rates.
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy